TScan Therapeutics (NasdaqGM:TCRX) FY Conference Transcript

TScan Therapeutics FY Conference Summary Company Overview - Company: TScan Therapeutics (NasdaqGM:TCRX) - Founded: 2018, out of Harvard Medical School - Focus: Next-generation TCR-T cell therapies for cancer treatment, utilizing technology to discover T cell targets in patients responding to immunotherapy [2][3] Key Clinical Programs Hematologic Malignancies - Lead Program: Targets patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Acute Lymphoblastic Leukemia (ALL) undergoing bone marrow transplants [3] - Clinical Data: - Presented data on 26 patients treated with TSC-100 and TSC-101, showing a relapse rate of 8% (2 out of 26) compared to 33% in the control arm [4][5] - Historical relapse rate for this patient population is about 40%, with a target of reducing it to 20% in the pivotal trial [7][9] - Pivotal Trial: Expected to launch in 2025, with a readout anticipated by the end of 2027 [5][16] Solid Tumor Program - Core Hypothesis: Treating patients with multiple TCR-T cell therapies simultaneously (multiplex therapy) to achieve deeper and longer-lasting responses [3][21] - Current Status: Seven different TCRs are in the same clinical trial, targeting various cancer-specific antigens [22] - Initial Data Release: Expected in Q1 2026, focusing on safety and efficacy data from approximately 8 to 10 patients [24] Market and Patient Demographics - Patient Population: Approximately 9,000 patients in the U.S. with AML, MDS, and ALL receive bone marrow transplants annually, primarily older patients who cannot tolerate intensive conditioning [8][10] - Unmet Need: High risk of relapse in patients undergoing reduced intensity conditioning, where TScan's therapy aims to improve cure rates [9] Safety and Efficacy - Safety Profile: The cell therapy product has shown to be well tolerated, with no significant increase in adverse events compared to the control arm [11] - Physician Feedback: High excitement among physicians, with a low bar for clinical meaningfulness; a 15% to 20% reduction in relapse rates would prompt usage [17] Expansion Plans - HLA Type Expansion: TScan is working on expanding its TCRs to other HLA types, including A0301 and A0101, which could double the addressable market [19][20] - ImmunoBank: A collection of TCRs targeting different cancer-specific antigens and HLA types to personalize treatment based on tumor expression [21][22] Financials and Capital Allocation - Cash Position: Approximately $218 million in cash and equivalents, providing a runway into the first half of 2027 [32] - Capital Prioritization: Focused on funding the pivotal trial and solid tumor program based on upcoming data readouts [32] Industry Context - Competitive Landscape: Monitoring developments in T cell therapy, particularly from China, while focusing on unique aspects of TCR-T therapy [33] - Regulatory Environment: Uncertainty at the FDA has impacted the biotech space, but cell therapy remains a core focus for the agency [38] Future Catalysts - Upcoming Milestones: - Updated data presentation at a major hematology conference by the end of the year [28] - Initial safety and efficacy data for multiplex therapy in Q1 2026 [28] Additional Insights - Autoimmunity Research: Ongoing partnerships and internal programs to discover T cell targets in autoimmune disorders, with plans to present findings at an upcoming medical conference [29][31]